Comments on “Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B”
Journal of Gastroenterology and Hepatology · 2026-08 · 41 (8) · 2523-2524
DOI: 10.1111/jgh.70539 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 26.06.2026. Verfasst von Waqar Ullah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
Autor:innen und Institutionen
- Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan.
ORCID-Profile: Waqar Ullah, Komal Ashok, Ahmad Shafi Antar
Zitieren
APA
Ullah, W., Ashok, K., & Antar, A. S. (2026). Comments on “Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B”. Journal of Gastroenterology and Hepatology, 41(8), 2523-2524. https://doi.org/10.1111/jgh.70539
Vancouver
Ullah W, Ashok K, Antar AS. Comments on “Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B”. Journal of Gastroenterology and Hepatology. 2026;41(8):2523-2524. doi:10.1111/jgh.70539
BibTeX
@article{Ullah2026,
author = {Ullah, Waqar and Ashok, Komal and Antar, Ahmad Shafi},
title = {Comments on “Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B”},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {8},
pages = {2523--2524},
doi = {10.1111/jgh.70539}
}
EUVIMED